Stomach cancer surgery plus two chemo plans
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two chemotherapy schedules around stomach cancer surgery: giving chemo before and after surgery (FLOT) versus giving chemo after surgery (XELOX). It’s meant to see which plan works better and is easier to tolerate for locally advanced disease that has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced stomach cancer (or the area where the food pipe meets the stomach) that has not spread to distant sites
- Your cancer is removable with surgery based on scans and staging
- You have not had chemotherapy before, and you have not had stomach surgery before
- You are age 18 to under 80
- Your overall health is fairly good (ECOG score 0 to 2) and your blood counts are adequate (hemoglobin, neutrophils, and platelets meet limits)
- Your kidneys and liver are healthy enough for chemo (kidney clearance is at least 50 mL/min; liver tests are within allowed limits), and pregnancy is not possible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
This trial compares two ways of giving chemotherapy before surgery for locally advanced stomach or stomach–esophagus cancer: chemo sent through an artery versus chemo given through an IV line. It also studies adding PD-1 immunotherapy to see which approach works better and is safer.
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Hear when a new Cancer of Stomach, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.